Literature DB >> 14615711

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.

Shelah Leader1, Kimmie Kohlhase.   

Abstract

OBJECTIVES: To provide current estimates of the incidence, associated risk factors, and costs of severe respiratory syncytial virus (RSV) infections among infants in the United States, defined as emergency department (ED) visits, hospitalization, and death. STUDY
DESIGN: Retrospective analysis of National Hospital Ambulatory Medical Care Survey data 1997 to 2000; National Hospital Discharge Survey data 1997 to 2000; Perinatal Mortality Linked Files 1998 to 1999. The Hospital Cost Utilization Inpatient Sample data 1997 to 2000 were used to estimate hospitalization costs, and the 2001 Medicare fee schedule was used to estimate ED visit costs. Census data were used for population estimates. Between 1997 and 2000, there were 718,008 ED visits by infants with lower respiratory infection diagnoses during the RSV season (22.8/1000), and 29% were admitted. Costs of ED visits were approximately 202 million US dollars. RSV bronchiolitis was the leading cause of infant hospitalization annually. Total hospital charges for RSV-coded primary diagnoses during the 4 years were more than 2.6 billion US dollars. An estimated 390 RSV-associated postneonatal deaths occurred in 1999. Low birth weight and prematurity significantly increased RSV-associated mortality rates.
CONCLUSIONS: RSV is a major cause of infant morbidity and mortality. Severe RSV is highest among infants of black mothers and Medicaid-insured infants. Prematurity and low birth weight significantly increase RSV mortality rates.

Entities:  

Mesh:

Year:  2003        PMID: 14615711     DOI: 10.1067/s0022-3476(03)00510-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  137 in total

Review 1.  Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

Authors:  Andrew A Colin; Cynthia McEvoy; Robert G Castile
Journal:  Pediatrics       Date:  2010-06-07       Impact factor: 7.124

2.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

3.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

4.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

5.  A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform.

Authors:  Minyoung Park; Hisae Matsuura; Robert A Lamb; Annelise E Barron; Theodore S Jardetzky
Journal:  Anal Biochem       Date:  2010-11-05       Impact factor: 3.365

6.  Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.

Authors:  Carla G García; Rafia Bhore; Alejandra Soriano-Fallas; Margaret Trost; Rebecca Chason; Octavio Ramilo; Asuncion Mejias
Journal:  Pediatrics       Date:  2010-11-22       Impact factor: 7.124

Review 7.  The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?

Authors:  Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla
Journal:  Paediatr Respir Rev       Date:  2019-04-12       Impact factor: 2.726

8.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

9.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03

10.  Pharmacological management of acute bronchiolitis.

Authors:  Melvin Wright; Charles J Mullett; Giovanni Piedimonte
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.